Sydnexis is a San Diego based clinical stage pharmaceutical company currently in the middle of a pivotal Phase 3 study, focused on the development of a novel proprietary formulation of low dose atropine for the treatment of myopia. Myopia is a growing public health challenge worldwide that’s expected to affect 5 billion people by the year 2050.
Employees: 11-50
Total raised: $45M
Founded date: 2014
Investors 4
| Date | Name | Website |
| - | Visionary ... | visionaryv... |
| - | RA Capital... | racap.com |
| 14.08.2021 | Longitude ... | longitudec... |
| - | Bluestem C... | bluestemca... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 10.08.2021 | Series B | $45M | Visionary ... |
Mentions in press and media 4
| Date | Title | Description | Source |
| 19.01.2024 | Sydnexis Welcomes Erin Horn as Vice President, Head of Marke... | DEL MAR, CALIFORNIA, USA, January 19, 2024 /EINPresswire.com/ -- January 19, 2023 – Sydnexis, Inc. (... | einpresswi... |
| 11.08.2021 | Sydnexis Raises $45M in Series B Funding | Sydnexis, a San Diego CA-based biopharmaceutical company, raised $45M in Series B funding. The roun... | finsmes.co... |
| 10.08.2021 | Sydnexis Closes $45M Series B Funding Round | SAN DIEGO, CA, Sydnexis today announced the completion of a $45 million Series B financing. >&... | vcnewsdail... |
| 10.08.2021 | Sydnexis Secures $45 Million Series B Financing Led by Visio... | Sydnexis, Inc., a clinical stage biopharmaceutical company with a proprietary formulation of low dos... | marketscre... |